Chongqing Genrix Biopharmaceutical (SHA:688443) received approval from China's National Medical Products Administration for the clinical trials of GR1803 injection, according to a Shanghai bourse filing on Friday.
The drug will be tested as a monotherapy in patients with relapsed or refractory multiple myeloma.
CTCI Engineering's (TWO:9933) new contract value hit nearly NT$75 billion as of early May, lifting the total value of projects under execution close to a record NT$500 billion, CNA reported, citing the company's investor conference.The company attributed the surge to rising demand tied to AI infrastructure and the global shift toward cleaner energy systems. It said high-tech projects made up 41% of new contracts in the first four months of the year, reflecting stronger exposure to data centres, semiconductors and high-performance computing-related infrastructure, according to the report.CTCI also highlighted a recent overseas win involving a US memory chip maker's project in Singapore, the report said.The company is expanding its strategy through a "Technology Engineering Strategic Alliance" with partners including Delta Electronics, Taiwan Polymer Group and Ta Ya Group, while also taking part in overseas industrial park initiatives across markets such as the US, Mexico, Poland and India, the news outlet added.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Kamat Hotels (India) (NSE:KAMATHOTEL, BOM:526668) signed an agreement to manage and operate a second property in Dwarka, Gujarat, under its flagship brand, The Orchid Hotel.The luxury property will have 63 rooms and is expected to become fully operational by December, according to a Thursday filing with the Indian bourses.
Hybio Pharmaceutical (SHE:300199) received approval from Indonesia's drug and food regulatory for the marketing of carbetocin injection, which trades as Uterocin, according to a Shenzhen bourse filing on Friday.The drug is used to reduce the risk of postpartum hemorrhage.The pharmaceutical company's shares jumped by less than 4% at the close.